Literature DB >> 7622829

Depot neuroleptics in relapse prevention: advantages and disadvantages.

J Gerlach1.   

Abstract

Non-compliance is a major problem in the treatment of schizophrenic patients, a problem which is due to the patient's mental condition, to disturbing side effects of the medication, to a defective doctor-patient relationship, and to a general scepticism towards chemical treatment of mental symptoms. The major advantage of depot administration of neuroleptic drugs is the assurance of compliance leading to fewer relapses and rehospitalizations. Depot neuroleptics also eliminate bioavailability problems related to absorption and first pass metabolism and give a stable plasma concentration. Finally, depot neuroleptics provide a better and safer way to use the lowest effective dose principle thereby reducing the frequency of side effects, including the subjectively distressing mental side effects such as akathisia, dysphoria and neuroleptic-induced deficit syndrome. Disadvantages include delayed disappearance of potentially irreversible and unpleasant side effects after discontinuation and, for many patients, a feeling of being controlled. Administered in the proper way, with suitable information to the patient and relatives, depot neuroleptics improve the quality of antipsychotic treatment, reduce relapse frequency, stabilize the therapeutic effect and diminish the level of side effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622829     DOI: 10.1097/00004850-199501005-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  10 in total

1.  Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Authors:  P S Chue; Bart Heeg; Erik Buskens; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 4.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.

Authors:  Stephane Cheung; Yukinobu Hamuro; Jörg Mahlich; Takanobu Nakahara; Rosarin Sruamsiri; Sunny Tsukazawa
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

7.  Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Authors:  Hyun-Ghang Jeong; Moon-Soo Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

8.  Perceptions and knowledge of antipsychotics among mental health professionals and patients.

Authors:  Lindah Cahling; Anders Berntsson; Gabriella Bröms; Lars Öhrmalm
Journal:  BJPsych Bull       Date:  2017-10

9.  Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder.

Authors:  Fabienne Chou; Earle Reome; Patricia Davis
Journal:  Ment Health Clin       Date:  2016-08-31

10.  Neuroleptic malignant syndrome in a young adult female at the university of Benin Teaching Hospital: a case report.

Authors:  Peter I Agbonrofo; John E Osakue
Journal:  Afr Health Sci       Date:  2018-09       Impact factor: 0.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.